Tenofovir disoproxil fumarate may not cause renal and bone toxicity in chronic hepatitis B patients: a retrospective cross-sectional study

References (5)

1. Gómez Martinez MV, Gallardo FG, Pirogova T, GarcíaSamaniego J. Bone scintigraphy and secondary osteomalacia due to nephrotoxicity in a chronic hepatitis B patient treated with tenofovir. Rev Esp Med Nucl Imagen Mol 2014; 33: 103- 105
2. Mateo L, Holgado S, Marinoso ML, Andres RP, Bonjoch A, Romeu J, Olive A. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 2016; 35: 1271-1279 3. Buchacz K, Brooks JT, Tong T, Moorman AC, Baker RK, Holmberg SD, Greenberg A, Wood KC, Armon C, Richardson JT et al. Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Medicine 2006; 7: 451-456
3. Wainwright E, Sherrard J, Duncan S, Shine B, Dorrell L. Hypophosphataemia with non-tenofovir-containing antiretroviral therapy. Int J STD AIDS 2013; 24: 579-581
4. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn Pet al. Dig Dis Sci 2015; 60: 1457-1464
5. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-988.